Novo Nordisk A/S (NVO) : Novo Nordisk A/S (NVO) had a healthy money flow of $0.89 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $22.04 million, whereas, investors only sold shares worth $21.16 million on downticks. The stock closed the day with an up-down ratio of 1.04.The money flow in the block trades to the tune of $2.87 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $2.87 million worth of transactions were on upticks. Novo Nordisk A/S (NVO) stock slid $0.49 intraday and traded at 45.86, a change of -1.05% over previous days close. However, for the week, the company shares are -2.21% compared to previous weeks close.
Institutional Investors own 7.34% of Novo Nordisk A/S shares.
Novo Nordisk A/S (NYSE:NVO): stock was range-bound between the intraday low of $45.36 and the intraday high of $45.925 after having opened at $45.41 on Fridays session. The stock finally closed in the red at $45.41, a loss of -1.17%. The stock remained in the red for the whole trading day. The total traded volume was 3,972,647 shares. The stock failed to cross $45.925 in Fridays trading. The stocks closing price on Thursday was $46.34.
Novo Nordisk A/S (NVO) : During the past 4 weeks, traders have been relatively bearish on Novo Nordisk A/S (NVO), hence the stock is down -8.04% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.81% relative to the S&P 500. The 4-week change in the price of the stock is -8.16% and the stock has fallen -2.32% in the past 1 week.
Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It has a range of diabetes product portfolio, including a portfolio of modern insulins as well as a human once-daily GLP-1 analog. It operates in two segments: diabetes care and biopharmaceuticals. The Companys diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Its biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. The primary production facilities owned by the Company are located at a number of sites in Denmark, and internationally in the United States, France, China and Brazil.